Could Therapeuticsmd Inc (NASDAQ:TXMD) Skyrocket? The Stock Had Too Little Sellers

March 14, 2018 - By Darrin Black

 Could Therapeuticsmd Inc (NASDAQ:TXMD) Skyrocket? The Stock Had Too Little Sellers

Investors sentiment increased to 1.73 in Q3 2017. Its up 0.69, from 1.04 in 2017Q2. It is positive, as 9 investors sold TherapeuticsMD, Inc. shares while 28 reduced holdings. 24 funds opened positions while 40 raised stakes. 162.04 million shares or 5.51% more from 153.57 million shares in 2017Q2 were reported.
Price T Rowe Associates Md has 0.01% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD). Stifel Financial Corporation owns 2.04M shares or 0.04% of their US portfolio. Natl Bank Of Ny Mellon Corp holds 25.88 million shares or 0.04% of its portfolio. Guggenheim Capital reported 76,333 shares or 0% of all its holdings. Alpine Woods Cap Ltd has invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Principal Financial Grp Inc has invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Virtu Financial Limited Liability Corporation invested in 0% or 69,058 shares. Carl Domino Incorporated reported 36,500 shares. Public Employees Retirement Association Of Colorado has invested 0% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD). Metropolitan Life Insurance Ny reported 102,975 shares. California State Teachers Retirement Sys accumulated 249,825 shares or 0% of the stock. Moreover, Sg Americas Ltd Liability Co has 0% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD). Geode Cap Mngmt Ltd Liability Corporation owns 1.34M shares or 0% of their US portfolio. Great West Life Assurance Co Can holds 0% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 15,700 shares. Ing Groep Nv accumulated 0.03% or 267,962 shares.

The stock of Therapeuticsmd Inc (NASDAQ:TXMD) registered a decrease of 1.8% in short interest. TXMD’s total short interest was 52.41 million shares in March as published by FINRA. Its down 1.8% from 53.37 million shares, reported previously. With 1.72 million shares average volume, it will take short sellers 31 days to cover their TXMD’s short positions. The short interest to Therapeuticsmd Inc’s float is 30.45%.

The stock decreased 0.19% or $0.01 during the last trading session, reaching $5.27. About 696,827 shares traded. TherapeuticsMD, Inc. (NASDAQ:TXMD) has declined 46.30% since March 14, 2017 and is downtrending. It has underperformed by 63.00% the S&P500.

TherapeuticsMD, Inc. operates as a women??s health care product company. The company has market cap of $1.14 billion. The firm makes and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. It currently has negative earnings. The Company’s pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Another recent and important TherapeuticsMD, Inc. (NASDAQ:TXMD) news was published by which published an article titled: “TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and …” on March 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.